China Pharma Partnerships News Roundup September 2020
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology…
Tagged with China
Chinese Biotech Strategies: Biologics or Small Molecules?
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…
Chinese Biotech Strategies: The Pros & Cons of In-Licensing
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…
China Pharma News Roundup September 2020
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and…
Eli Lilly and Innovent take China Partnership Global
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear…
Kerry Blanchard – CEO, Everest Medicines, China
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist…
Biotech Spotlight: Alphamab Oncology, China
Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese…
China’s 3rd Drug Procurement Round: A Bloodbath for…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in…
China Pharma News Roundup August 2020
A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates…
Company Spotlight: I-Mab Biopharma
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced…
Zaiqi Wang – Chairman & CEO, InxMed, China
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment,…
HKEX SVP Reflects on Two Years of Pre-Revenue Biotech IPO…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as…
